Chronic Obstructive Pulmonary Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - AstraZeneca, Sanofi, GlaxoSmithKline, Glenmark Pharmaceut

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Chronic Obstructive Pulmonary Disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.
• Chronic Obstructive Pulmonary Disease companies working in the treatment market are GlaxoSmithKline, Glenmark Pharmaceuticals Ltd., Meridigen Biotech, Organicell Regenerative Medicine, Amgen, Synairgen, AstraZeneca, Sanofi, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment
• Emerging Chronic Obstructive Pulmonary Disease therapies such as - GSK3923868, GRC 39815, UMC119-06, Zofin, Tezepelumab, SNG001, Navafenterol, Benralizumab, SAR440340, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.
• In August 2019, AstraZeneca initiated a multicenter, randomized, double-blind, chronicdosing, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of Benralizumab 100 mg in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (RESOLUTE)
• In March 2019, Kyowa Hakko Kirin announced that the company had entered into new agreements with AstraZeneca granting AstraZeneca exclusive rights to benralizumab (brand name "Fasenra") for all additional indications in Asia, inclusive of Japan

Chronic Obstructive Pulmonary Disease Overview
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:
• GSK3923868: GlaxoSmithKline
• GRC 39815: Glenmark Pharmaceuticals Ltd
• UMC119-06: Meridigen Biotech
• Zofin: Organicell Regenerative Medicine
• Tezepelumab: Amgen
• SNG001: Synairgen
• Navafenterol: AstraZeneca
• Benralizumab: AstraZeneca
• SAR440340: Sanofi

Route of Administration
Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment
• Chronic Obstructive Pulmonary Disease Assessment by Product Type
• Chronic Obstructive Pulmonary Disease By Stage and Product Type
• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration
• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration
• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type
• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight's Chronic Obstructive Pulmonary Disease Report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies at:
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:
Key companies developing therapies for Chronic Obstructive Pulmonary Disease are - AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici SpA, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Orion Corporation, Merck & Co., Inc, Grifols, S.A., Abbott, F. Hoffmann-La Roche Ltd, Vectura Group plc, Pfizer Inc, Alkermes, Mylan N.V, Almirall, S.A, Genentech, Inc, Biogen, and Astellas Pharma Inc., and others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:
The Chronic Obstructive Pulmonary Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies-
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers
• Rising disease burden associated with COPD, increasing focus on therapy development • Favorable insurance coverage for COPD treatment are some of the important factors that are fueling the Chronic Obstructive Pulmonary Disease Market.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers
• However, Concerns regarding the long term use of current ICS/LABA inhalers, poor regimen adherence by patients, treatment costs and other factors are creating obstacles in the Chronic Obstructive Pulmonary Disease Market growth.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight
• Coverage: Global
• Key Chronic Obstructive Pulmonary Disease Companies: GlaxoSmithKline, Glenmark Pharmaceuticals Ltd., Meridigen Biotech, Organicell Regenerative Medicine, Amgen, Synairgen, AstraZeneca, Sanofi, and others
• Key Chronic Obstructive Pulmonary Disease Therapies: GSK3923868, GRC 39815, UMC119-06, Zofin, Tezepelumab, SNG001, Navafenterol, Benralizumab, SAR440340, and others
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

Request for Sample PDF Report for Chronic Obstructive Pulmonary Disease Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Chronic Obstructive Pulmonary Disease Report Introduction
2 Chronic Obstructive Pulmonary Disease Executive Summary
3 Chronic Obstructive Pulmonary Disease Overview
4 Chronic Obstructive Pulmonary Disease- Analytical Perspective In-depth Commercial Assessment
5 Chronic Obstructive Pulmonary Disease Pipeline Therapeutics
6 Chronic Obstructive Pulmonary Disease Late Stage Products (Phase II/III)
7 Chronic Obstructive Pulmonary Disease Mid Stage Products (Phase II)
8 Chronic Obstructive Pulmonary Disease Early Stage Products (Phase I)
9 Chronic Obstructive Pulmonary Disease Preclinical Stage Products
10 Chronic Obstructive Pulmonary Disease Therapeutics Assessment
11 Chronic Obstructive Pulmonary Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Chronic Obstructive Pulmonary Disease Key Companies
14 Chronic Obstructive Pulmonary Disease Key Products
15 Chronic Obstructive Pulmonary Disease Unmet Needs
16 Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
17 Chronic Obstructive Pulmonary Disease Future Perspectives and Conclusion
18 Chronic Obstructive Pulmonary Disease Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Chronic Obstructive Pulmonary Disease Market
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Obstructive Pulmonary Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Chronic Obstructive Pulmonary Disease Epidemiology
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Obstructive Pulmonary Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.